Sign in

    Edward Nash

    Managing Director and Senior Biotechnology Analyst at Canaccord Genuity

    Edward Nash is a Managing Director and Senior Biotechnology Analyst at Canaccord Genuity, specializing in healthcare with an emphasis on companies developing innovative antibiotics, treatments for liver disease, metabolic conditions, and inflammation and immunology. He covers 68 stocks, including firms such as Verona Pharma, Madrigal Pharmaceuticals, and Travere Therapeutics, and holds a TipRanks success rate of 48% and an average return of 16.6% per rating, with standout calls like a 507% return on VRNA. Nash began his Wall Street career during the Dot Com Bubble, previously serving in senior research positions at Cowen and SunTrust Robinson Humphrey before joining Canaccord Genuity in New York; he has nearly 20 years of biotechnology experience. He holds an MBA from the University of Miami, an MPH from the University of Alabama at Birmingham, a BA from Spring Hill College, and possesses FINRA registration and relevant securities licenses.

    Edward Nash's questions to CORCEPT THERAPEUTICS (CORT) leadership

    Edward Nash's questions to CORCEPT THERAPEUTICS (CORT) leadership • Q2 2025

    Question

    Speaking for Edward Nash of Canaccord Genuity, Xinwei asked about relacorilant's positioning in ovarian cancer, physician sentiment on its use in early vs. late-stage disease, and potential overlapping toxicities in future combination therapies.

    Answer

    Roberto Vieira, President of Oncology, outlined a path to market leadership in platinum-resistant ovarian cancer, projecting over $1 billion in long-term revenue, supported by flexible use across therapy lines. He and CEO Joseph Belanoff noted strong physician interest for use in earlier lines due to the drug's efficacy and safety. Chief Development Officer William Guyer stated there are no concerns about overlapping toxicities with other agents.

    Ask Fintool Equity Research AI

    Edward Nash's questions to CORCEPT THERAPEUTICS (CORT) leadership • Q1 2025

    Question

    Edward Nash asked about the oncology program, specifically the treatment paradigm for relacorilant versus competitors like Elahere and any feedback from oncologists on the ROSELLA data. He also inquired about the revenue cadence for the remainder of the year, questioning if a large bolus should be expected in Q2 following the resolution of pharmacy issues.

    Answer

    Roberto Vieira, President of the Oncology division, explained that relacorilant plus nab-paclitaxel is positioned to become a new standard of care in platinum-resistant ovarian cancer and can be used before or after biomarker-driven agents. Sean Maduck, President of the Endocrinology division, and CEO Joseph K. Belanoff clarified that they do not expect a single revenue bolus in Q2, but rather accelerating growth throughout the rest of the year.

    Ask Fintool Equity Research AI

    Edward Nash's questions to Galmed Pharmaceuticals (GLMD) leadership

    Edward Nash's questions to Galmed Pharmaceuticals (GLMD) leadership • Q2 2021

    Question

    Edward Nash from Canaccord Genuity inquired about the patient composition of the initial 50-subject open-label ARMOR study data expected in Q4 2021 and sought confirmation that the registrational part of the trial would be powered based on the blinded study using only Aramchol meglumine.

    Answer

    President and CEO Allen Baharaff clarified that the initial 50-patient cohort is a randomized mix of subjects from the 24, 48, and 72-week biopsy groups, not just the 24-week group. He confirmed that while open-label safety data supports the NDA, the study's powering and efficacy analysis for a potential accelerated approval submission will be based on the blinded portion of the trial using the higher-exposure Aramchol meglumine.

    Ask Fintool Equity Research AI

    Edward Nash's questions to Galmed Pharmaceuticals (GLMD) leadership • Q2 2021

    Question

    Edward Nash of Canaccord Genuity asked for clarification on the patient cohort structure for the open-label ARMOR Phase III study and confirmed that the pivotal, blinded portion of the trial would exclusively use the new Aramchol meglumine formulation for its accelerated approval submission.

    Answer

    Executive Allen Baharaff clarified that the initial 50 patients are a randomized mix of the 24, 48, and 72-week biopsy groups, not sequential cohorts. He confirmed the blinded part of the study will use Aramchol meglumine for the NDA submission and that the open-label data is crucial for determining safety, optimal treatment duration, and the final powering of the study, given the higher drug exposure.

    Ask Fintool Equity Research AI